Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBITDA (2016 - 2025)

Adma Biologics (ADMA) has disclosed EBITDA for 13 consecutive years, with $62.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 63.75% year-over-year to $62.8 million, compared with a TTM value of $191.4 million through Dec 2025, up 37.75%, and an annual FY2025 reading of $191.4 million, up 37.75% over the prior year.
  • EBITDA was $62.8 million for Q4 2025 at Adma Biologics, up from $51.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $62.8 million in Q4 2025 and bottomed at -$15.6 million in Q2 2021.
  • Average EBITDA over 5 years is $12.7 million, with a median of $4.1 million recorded in 2023.
  • The sharpest move saw EBITDA dropped 4.61% in 2021, then soared 8387.74% in 2024.
  • Year by year, EBITDA stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then skyrocketed by 334.93% to $14.2 million in 2023, then soared by 169.25% to $38.3 million in 2024, then soared by 63.75% to $62.8 million in 2025.
  • Business Quant data shows EBITDA for ADMA at $62.8 million in Q4 2025, $51.0 million in Q3 2025, and $42.8 million in Q2 2025.